Review
Nature Reviews Drug Discovery 7, 504-516 (June 2008) | doi:10.1038/nrd2530
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio1, Silvia Giordano1 & Livio Trusolino1 About the authors
Abstract
The MET tyrosine kinase stimulates cell scattering, invasion, protection from apoptosis and angiogenesis, thereby acting as a powerful expedient for cancer dissemination. MET can also be genetically selected for the long-term maintenance of the primary transformed phenotype, and some tumours appear to be dependent on (or 'addicted' to) sustained MET activity for their growth and survival. Because of its dual role as an adjuvant, pro-metastatic gene for some tumour types and as a necessary oncogene for others, MET is a versatile candidate for targeted therapeutic intervention. Here we discuss recent progress in the development of molecules that inhibit MET function and consider their application in a subset of human tumours that are potentially responsive to MET-targeted therapies.
- View At a Glance
Author affiliations
- Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Turin School of Medicine, Candiolo, Turin 10060, Italy.
Correspondence to: Paolo M. Comoglio1 Email: paolo.comoglio@ircc.it
Correspondence to: Livio Trusolino1 Email: livio.trusolino@ircc.it
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Angiogenesis inhibitors: motivators of metastasis?Nature Medicine News and Views (01 Jul 2003)
Novel effector function for an old receptorNature Cell Biology News and Views (01 Jan 2002)
RESEARCH
A GTP-binding adapter protein couples TRAIL receptors to apoptosis-inducing proteinsNature Immunology Article (01 Jun 2001)
Hypothetical biotechnology mega-mergersNature Biotechnology Strategic Planning (01 May 1999)
See all 34 matches for Research
